A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model by Gattenlöhner, S. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 187621, 11 pages
doi:10.1155/2010/187621
Research Article
AHuman RecombinantAutoantibody-Based Immunotoxin
SpeciﬁcfortheFetal AcetylcholineReceptorInhibits
Rhabdomyosarcoma Growth In Vitro and in a Murine
Transplantation Model
S. Gattenl¨ ohner,1 H.J¨ orißen,2 M. Huhn,3 A. Vincent,3 D. Beeson,3 S.Tzartos,4 A.Mamalaki,4
B. Etschmann,1 H. K. Muller-Hermelink,1 E.Koscielniak,5 S.Barth,2,6 andA.Marx1,7
1Institute of Pathology, University of W¨ urzburg, 97080 W¨ urzburg, Germany
2Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology,
Forckenbeckstraße 6, 52074 Aachen, Germany
3Neurosciences Group, Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, University of Oxford,
OX3 9DU Oxford, UK
4Hellenic Pasteur Institute, 127, Vas. Soﬁas Avenue 11521, Athens, Greece
5Department of Pediatric Oncology, Olga Hospital, 70176 Stuttgart, Germany
6Department of Experimental Medicine and Immunotherapy, Helmholtz-Institute for Biomedical Engineering,
University Hospital RWTH Aachen, Pauwelsstraße 20, 52074 Aachen, Germany
7Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Theodor-Kutzer Ufer 1-3,
68135 Mannheim, Greece
Correspondence should be addressed to S. Gattenl¨ ohner, stefan.gattenloehner@mail.uni-wuerzburg.de
Received 14 August 2009; Accepted 18 November 2009
Academic Editor: Rene Anand
Copyright © 2010 S. Gattenl¨ ohner et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children and is highly resistant to all forms of
treatment currently available once metastasis or relapse has commenced. As it has recently been determined that the acetylcholine
receptor (AChR) γ-subunit,whichdeﬁnesthefetalAChR(fAChR)isoform,isalmostexclusivelyexpressedinRMSpostpartum,w e
recombinantlyfusedasinglechainvariablefragment(scFv)derivedfromafullyhumananti-fAChRFab-fragmenttoPseudomonas
exotoxin A to generate an anti-fAChR immunotoxin (scFv35-ETA). While scFv35-ETA had no damaging eﬀect on fAChR-negative
control cell lines, it killed human embryonic and alveolar RMS cell lines in vitro and delayed RMS development in a murine
transplantation model. These results indicate that scFv35-ETA may be a valuable new therapeutic tool as well as a relevant step
towards the development of a fully human immunotoxin directed against RMS. Moreover, as approximately 20% of metastatic
malignant melanomas (MMs) display rhabdoid features including the expression of fAChR, the immunotoxin we developed may
also prove to be of signiﬁcant use in the treatment of these more common and most often fatal neoplasms.
1.Introduction
Three forms of RMS are recognized, each of which shows
skeletalmusclediﬀerentiation,butaredistinguishedbyother
genetic and biological characteristics: (1) embryonal RMS,
characterized by loss of heterozygosity at 11p15; (2) the
more aggressive alveolar RMS, often accompanied by Pax3
or Pax7-FKHR gene fusions resulting from translocations
t(2;13) (q35; q14) and t(1; 13) (p36; q14), respectively; and
(3) the rare pleomorphic RMS, which is genetically complex
a n dt e n d st oo c c u ri na d u l t s[ 1]. As a group, RMS is the
most frequent soft tissue tumor in children [2]. Metastatic2 Journal of Biomedicine and Biotechnology
alveolar RMS in children older than 10 years as well as
relapse of disease tends to be refractory to all current forms
of therapy including adjuvant bone marrow transplantation
[3], resulting in 5-year survival rates of no more than 5–
20% [2–4]. Therefore, novel ﬁrst line or adjuvant treatment
strategiesareurgentlyneededforhigh-riskRMSpatients[5].
As we have previously shown that, after birth, the fetal AChR
(fAChR) is almost exclusively expressed in RMS [6–8]a n d
that anti-fAChR chimeric T-cells could kill fAChR-positive
RMS cell lines in vitro [9], this target seemed promising for
the development of an immunotoxin, a molecule consisting
of a toxin coupled to an antibody fragment designed to
destroy a speciﬁc type of cell [10]. Therefore, we generated
an immunotoxin targeting fAChR in order to exploit its
expression pattern for the treatment of RMS.
The nicotinic Acetylcholine Receptor (AChR) is a pen-
tamericionchannelwhichappearsinanembryonic(fAChR)
and an adult isoform (AChR). Both isoforms comprise
two α,o n eβ,a n do n eδ subunits, while the γ-subunit is
speciﬁc for fAChR. In the process of muscle innervation
during embryonic development, the γ-subunit is replaced
by an ε-subunit, leading to the replacement of fAChR by
AChR. After birth, expression of fAChR is restricted to
few tissue forms including extraocular muscle ﬁbers of
unknown function [11–13], thymus myoid cells [14–16],
and skeletal muscles following denervation [17, 18]. In
contrast, the vast majority of human embryonic and alveolar
rhabdomyosarcomas strongly express fAChR on the tumor
cell surface [6–8], making this receptor ideal for immune-
targeting by an immunotoxin.
Several disorders involving the immunization against
fAChR shed light on the molecular mechanisms of anti-
fAChR antibodies. In myasthenia gravis (MG), an autoim-
mune disease most commonly caused by the appearance
of anti-AChR autoantibodies [19], the majority of patients
develop autoantibodies against AChR as well as fAChR [19,
20]. In studies of MG, it has been shown that anti-AChR
autoantibodies are internalized along with AChR after bind-
ing, which is a necessary mechanism for an immunotoxin
against RMS to exert its eﬀect on target cells [19]. The
unborn children of parous pregnant women who developed
autoantibodies against fAChR can develop arthrogryposis
multiplex following diaplacentar passage of these antibodies,
while their mothers remain free of symptoms. This not only
shows that the γ-subunit of fAChR harbors immunologically
speciﬁc epitopes that are potentially suitable as target for an
immunotoxin in the therapy of RMS but also suggests that
the use of an anti-fAChR immunotoxin in RMS treatment
is unlikely to induce serious side eﬀects [21]. Finally, cDNA
libraries derived from MG patients and mothers of children
suﬀering from arthrogryposis multiplex should be ideal
sources for the generation of fAChR-antibodies in vitro.
This report is the ﬁrst description of the cloning, expres-
sion and functional testing of an immunotoxin targeting
the AChR γ-subunit. The immunotoxin consists of an scFv
antibody fragment derived from a human combinatorial
thymus cDNA library prepared from a woman producing
autoantibodies against fetal AchR [21] and a truncated
version of the pseudomonas exotoxin A. This toxin killed
RMS cells in vitro and delayed tumor growth in a murine
transplantation model.
2. Results
2.1.AnImmunotoxinTargetingtheMainImmunogenicRegion
(MIR) of the AChR α-Subunit Kills RMS Cells In Vitro.
Initially, we generated an immunotoxin containing ETA
based on a recombinant single chain Fv fragment derived
from the rat monoclonal antibody mAb192 against the main
immunogenic region (MIR) of the human AChR α-subunit
[22, 23]. This model immunotoxin (scFv192-ETA) bound
to several RMS cell lines and killed the RMS cell lines
TE-671, FL-OH-1 and RD in a dose-dependent manner,
while fAChR-negative RMS and non-RMS hematopoietic
control cell lines (A-204, U937) were killed only at much
higher immunotoxin concentrations (not shown). These
experiments showed that an immunotoxin targeting AChR
is able to kill AChR-positive RMS cells in vitro while leaving
AChR-negative cell lines relatively unharmed.
2.2. Construction and In Vitro Characterization of Immuno-
toxins Targeting the γ-Subunit of Human Fetal AChR. Subse-
quently, we generated an ETA-based immunotoxin targeting
the AChRγ-subunit, which is speciﬁc for the fetal form of
the AChR. Two recombinant human Fab fragments (Fab35
and Fab38) were isolated from a combinatorial cDNA library
derived from the thymus of a seropositive MG patient
with high titers of anti-AChR γ-subunit antibodies [21].
Although the two Fab fragment cDNAs were inserted in-
frame into the ETA-vector, they were translated ineﬃciently
in E. coli BL21DE3, resulting in several abnormal protein
fragments of 70–80kDa instead of the expected 120kDa
full-length product (not shown). Therefore, we used the
Fab35 and Fab38 cDNAs to produce single-chain Fv (scFv)
fragments by overlap extension PCR (Figure 1). VH and VL
fragments were linked by a 36-nucleotide (glycine/serine)
spacer to produce scFv fragments with a VH-VL and a VL-
VH orientation fromboth Fabs, yielding fourdiﬀerent scFvs.
The four scFv cDNAs were inserted into the ETA vector
pBM-1.0, checked for proper ligation by sequencing and
expressed in E. coli BL21DE3. The resulting immunotoxins
were puriﬁed and the binding capacity to RMS cells was
determined by ﬂow cytometry. Of the four molecules
examined, only the Fab35 derivative scFv35/VL-VH-ETA
speciﬁcally bound to cells of the fAChR-positive embryonal
RMS cell lines TE-671, RD, and FL-OH-1 as well as to
the alveolar RMS cell lines RH-30 and Ax-OH-1 and while
showing virtually no reactivity with the fAChR-negative
control RMS line A-204 or the hematopoietic cell line U937
(Figure 2).
This immunotoxin, termed scFv35-ETA, killed fAChR-
positiveRMS cell lines in a dose-dependent manner, while
it had almost no eﬀect on the control cell lines A-204 and
U937 (Figures 3(a) and 3(b)). Speciﬁcity of the growth
inhibitory eﬀect was demonstrated using a nonbinding
control composed of a non-binding scFv fused to ETA
(mock-ETA). The IC50 values of scFv35-ETA and the controlJournal of Biomedicine and Biotechnology 3
Table 1: Comparison of IC50 values of scFv35-ETA and mock-ETA control on various cell lines.
Mean IC50 (nM)
TE-671 RD FL-OH-1 Ax-OH-1 RH-30 U937 A-204
scFv35-ETA 34 1.5 0.13 14 113 >500 >500
mock-ETA 113 22 12 90 >500 >500 >500
IC50 values indicating concentrations required to achieve a 50% reduction of protein synthesis relative to untreated control cells as derived from colorimetric
XTT assay in Figure 3.
Sﬁ I 1
2 Linker
3 Linker
4 NOT I
VII5 -PCR-sense primer with integrated Sﬁ I site at the 5  end
VII3 -PCR-antisense primer with overhanging 36nt. glycine/serine linker at the 3  end
VL5 -PCR-sense primer with overhanging 36nt. glycin/serin linker at the 5  end
VL3 -PCR-antisense primer with integrated NOT I site at the 3  end
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Figure 1: Schematic presentation of the synthesis of scFv fragments based on the recombinant Fab fragments Fab35 and Fab38 [21] using
overlap extension PCR.
immunotoxin on the tested cell lines are summarized in
Table 1. The inhibitory eﬀect could be signiﬁcantly enhanced
using the fAChR-speciﬁc scFv35-ETA as shown by a decrease
of IC50 values ranging from 3 (TE-671) to 100-fold (FL-OH-
1). Furthermore, addition of 100-fold molar excess of free
scFv35 in a competitive approach could completely knock-
down the toxic eﬀect of scFv35-ETA fusion protein emp-
hazising its speciﬁcity (Figure 3(c)). To further characterize
the toxic eﬀect of scFv35-ETA on RMS cells, an annexin V-
basedapoptosis assaywasperformedonembryonalRMScell
line RD. The amount of cells staining positive for annexin V,
an early apoptosis marker, clearly increased during the time
points of 12, 14, and 48 hours of incubation. Finally, after 48
hours a total of 51,7 % of cells incubated with scFv35-ETA
stained positive for annexin V compared to 9.28 in the PBS
control (Figure 4).
2.3. The γ-Subunit-Speciﬁc Immunotoxin Delays Tumor
Development in a Mouse RMS Transplantation Model. The
in vivo toxicity of scFv35-ETA against RD RMS cells was
tested in a murine RMS transplantation model [24]. Initial
tests on healthy SCID mice revealed that intraperitoneal
injection of 10μg scFv35-ETA per mouse (n = 10) had
no apparent adverse eﬀects on mobility, weight gain, or
survival (up to 60 days). Therefore, this dose was used in
concert with the subcutaneous injection of 5 × 106 RD cells
per mouse (n = 10), with saline injections as controls
(n = 4). Twice daily injections of 10μg scFv35-ETA per
mouse were repeated up to day 10. Tumor development was
monitored by daily inspection and palpation. As shown in
Figure 4, 100% of mock injected mice developed palpable
tumors by day 7 of the experiment and clearly visible
subcutaneous tumors by day 10 (volume: 59 +/− 9mm 3).4 Journal of Biomedicine and Biotechnology
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Figure 2: FACS Analysis of scFv35-ETA.
In contrast, the mice injected with the immunotoxin showed
little evidence of tumor development by day 7 and no
visible sign of subcutaneous tumor development by day
10, although smaller tumors could be palpated (volume:
8+ /−27mm3). Until day 12, the tumors in the treated
group were signiﬁcantly smaller than those in the controls.
After ﬁnishing the course of daily immunotoxin injections,
however, subcutaneous tumors began to enlarge rapidly in
the test group and reached the same size as the tumors in the
control group by day 14 (Figure 4).
3. Discussion
In our study, which involved the development of an
immunotoxin against RMS, we report three major newJournal of Biomedicine and Biotechnology 5
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Figure 3:ColorimetricXTTcytotoxicity assays with various immunotoxin concentrations (n = 3 parallel cell cultures per dilution) showing
strong dose-dependent toxicity of the immunotoxin scFv35-ETA directed against the acetylcholine receptor (AChR) γ-subunit on positive
RMS cell lines TE671, RD, and FL-OH-1, RH-30 and Ax-OH-1 even at higher dilutions (a). Lower to no toxicity of the immunotoxin were
observedtowardsthecontrolcelllinesA-204andU937notexpressingfAChR(b).Competitionoftoxicitycouldbeachievedwith1–100-fold
molar excess (C 1.5–150nM) of scFv35 added to cells incubated with 1.5nM scFv35-ETA, whereas scFv35 alone does not inhibit cell growth
even at 100 fold higher concentration (c). Cell viability is expressed as percentage inhibition of cell proliferation compared to non-treated
cells.
ﬁndings: (1) we showed that the major immunogenic
region of the nicotinic AChR α-subunit can be used as an
immunotoxin target to kill RMS cells in vitro, (2) we were
able to generate a human scFv autoantibody fragment that
binds to the AChR γ-subunit of human RMS cell lines, and
(3) a recombinant ETA-based immunotoxin derived from
this antibody fragment killed human RMS cells in vitro and
signiﬁcantly delayed tumor development in a mouse RMS
transplantation model, although it alone was insuﬃcient to
cure the disease.
Antibody-based immunotherapy is a well-established
method in the treatment of various tumor types, such as
ErbB2-positive breast cancer [25], Hodgkin lymphoma [26–
30], acute myeloid leukemia [31–33], colon cancer [34,
35], lung cancer [36], melanoma [37], and neuroblastoma
[38–40]. However, immunotoxin therapy has not yet been
applied to RMS, as an antigen expressed speciﬁcally and at
high levels on the surface of these tumor cells was not known
until recently [9]. This obstacle was overcome when we
found that the fetal AChR isoform (fAChR) is expressed on
thesurfaceofthevastmajorityofRMScells,whileitisabsent
from normal innervated muscles [6, 9, 18]. Recently, we
showed that anti-fAChR chimeric T-cells could kill fAChR-
positive RMS cell lines in vitro while fAChR-negative cells
remained unharmed [9]. However, chimeric T-cells based
on antibody fragments linked to T-cell receptor subunits
( s u c ha st h eζ-chain) are notoriously susceptible to deletion
and anergy in vivo [41], suggesting that an immunotoxin
speciﬁc for the same epitope would be a more promising
approach.6 Journal of Biomedicine and Biotechnology
12h
7.8
6.04
P
B
S
c
o
n
t
r
o
l
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(a)
24h
4.12
5.26
P
B
S
c
o
n
t
r
o
l
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(b)
48h
6.4
2.88
P
B
S
c
o
n
t
r
o
l
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(c)
12h
7.1
3.76
s
c
F
v
3
5
E
T
A
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(d)
24h
10.14
10.12
s
c
F
v
3
5
E
T
A
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(e)
48h
38.36
13.34
s
c
F
v
3
5
E
T
A
,
P
I
100
101
102
103
104
AV-GFP
100 101 102 103 104
(f)
Figure 4: Annexin V apoptosis assay on RD cells incubated with either scFv35-ETA or PBScontrol for 12, 14 and 48 hours. Quadrants
distinguish viable cells (lower left), early apoptotic cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper left).
Numbers indicate percentage of early and late apoptotic cells, respectively.
Therefore, we set out to generate an immunotoxin to
target fAChR by ﬁrst expressing a fusion protein between
an anti-AChR antibody fragment and the Pseudomonas
exotoxin A (scFv192-ETA). In these experiments, we found
proof that scFv192-ETA kills RMS cells in vitro, while
leavingAChR-negativecontrolcelllinesrelativelyunharmed.
These data also show that fusion of scFv192 to a truncated
Pseudomonas exotoxin A and expression in bacteria has
no detrimental eﬀect on the binding speciﬁcity of the
rat antibody fragment [22]. Subsequently, we constructed
immunotoxins speciﬁc for the AChR γ-subunit by using
two recombinant human Fab fragments (scFv35 and scFv38)
known for their speciﬁcity and strong aﬃnity for the γ-
subunit of the AchR [21] and generated four diﬀerent scFv
derivatives. A human antibody fragment was chosen ﬁrstly
as there are no easily available well-characterized mouse or
rat monoclonal antibodies with γ-subunit speciﬁcity and
secondly because human anti-AChR autoantibodies from
MG patients are known for their high aﬃnity and speciﬁcity,
properties that are often conserved in recombinant Fab
or single chain Fv derivatives [22, 42, 43]. Furthermore,
human monoclonal autoantibody fragments are preferable
as immunotoxin components as they are less likely to be
immunogenic than their rodent counterparts and could
pave the way towards the development of a fully human
immunotoxin using a human toxin component such as
ar i b o n u c l e a s e[ 28]o ra ne ﬀector such as an interleukin
[44]. Surprisingly, only one of the immunotoxins generated
(scFv35-ETA) showed signiﬁcant binding to cell lines with
abundant, surface-displayed fetal AChR. As myasthenia
gravis autoantibodies critically depend on the 3-dimensional
conformationoftheirbindingsitesonseveralAChRsubunits
[45], it is likely that steric hindrance prevented eﬃcient
binding of the three unsuccessful variants. ScFv35-ETA was
cytotoxic to RMS cells both in vitro (Figures 3and4)andina
pilot in vivo mouse model (Figure 5). For the eﬃcacy studies
c e l ll i n e sf r o mb o t he m b r y o n a la n da l v e o l a rs u b t y p ew e r e
chosen that have all previously been shown to express fAChR
on the cell surface, indicating the responsiveness of both
subtypes to scFv35-ETAe. The speciﬁcity of scFv35-ETA was
conﬁrmed in vitro by the lack of toxicity in control cells not
expressingfAChRandbycompetitionoftoxicitywithscFv35
alone as well as in vivo in the 10 mice administered 20μg
immunotoxin per day. This was not surprising, as carriersJournal of Biomedicine and Biotechnology 7
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Figure 5: In vivo eﬀect of scFv35-ETA on RD embryonal RMS cells
(5 × 106 RD cells per mouse) transplanted subcutaneously into
SCID mice. The ﬁrst intraperitoneal immunotoxin injection (10μg
twice daily) was carried out 2 days after the injection of tumor cells
and repeated daily until day 10.
of autoantibodies against fAChR are generally completely
asymptomatic [21], although it is known that, after birth,
fAChR is expressed in certain extraocular muscle ﬁbers [12],
thymic myoid cells [14], and skeletal muscles following
denervation [17, 18].
However, the “single agent” in vivo treatment of mice
with scFv35-ETA for 10 days did not cure the animals,
as tumor growth was signiﬁcantly delayed but not totally
blocked as long as the immunotoxin was administered and
progressed rapidly after the end of treatment. Among the
known mechanisms leading to immunotoxin resistance, the
poor vascularization of sarcomas [37, 46] is the most likely
reason for this shortfall in therapeutic eﬃcacy. However, this
could be addressed by dose elevation as well as prolonged
administration, an approach in which the use of a fully
human immunotoxin may be necessary to circumvent
sensitization against a mouse, rat, or humanized antibody
component [37, 46].
In addition, other strategies to improve the treatment
of RMS using scFv35-based immunotoxins can be envis-
aged. First, there are well-established techniques to stabilize
immunotoxins [47], increase their aﬃnity [47], and improve
their uptake into tumor cells [48]. Second, as shown in
leukemia [49], the therapeutic eﬀect of immunotoxins can
be improved when the expression level of the target antigen
and the percentage of target-positive tumor cells are ele-
vated pharmacologically. Third, single-agent antibody-based
therapies can be made more eﬃcient when combined with
traditional chemotherapies or the targeted application of
cytokines, chemokines, antiangiogenic agents, or modiﬁers
of degradation pathways that inactivate toxins [44, 50–
59]. Any or all of these strategies could be applied to
the treatment of RMS using scFv35-ETA. For example, it
has previously been shown that chemotherapy can induce
the diﬀerentiation of immature, AChR
low RMS cells to
more mature rhabdomyoblasts with increased expression
of muscle speciﬁc proteins including fetal AChRs [9, 60].
Thus, the synchronous or metachronous application of
chemotherapy and scFv35-ETA could be more successful
in treating RMS than scFv35-ETA alone. However, further
preclinical trials are needed to substantiate whether any of
the strategies described above actually have a positive impact
on the eﬃcacy of RMS treatment using scFv35-ETA.
In summary, we have shown that the fetal AChR is a
speciﬁc marker of human RMS that can be recognized by
a scFv-based immunotoxin (scFv35-ETA). Our experiments
showed that the immunotoxin, the ﬁrst sarcoma-directed
agent based on a fully human autoantibody fragment
described so far, was eﬀective both in vitro and in vivo
against RMS cells and is therefore a promising candidate for
further preclinical development. This would include the use
of more reﬁned murine RMS transplantation models using
ab r o a ds p e c t r u mo fR M Sc e l ll i n e sa sw e l la sm o l e c u l a r
modiﬁcation of the immunotoxin for better stability and
higher binding aﬃnity in vivo as well as the coupling of
the immunotoxin to human toxins or alternative eﬀectors.
Finally, our recent observation that a subgroup of metastatic
malignant melanomas (MMs) can transdiﬀerentiate into
fAChR-expressing RMS-like cells [61] suggests that a reﬁned
fAChR-directed immunotoxin may also be of signiﬁcant use
in the treatment of these tumors and may therefore have a
broaderspectrumoftherapeuticindicationsthananticipated
so far.
4. Methods
4.1. Generation of Anti-AChR Fab and scFv Fragments. The
cloning and expression of the high-aﬃnity rat scFv192
fragment derived from the rat anti-AChR antibody mAb192
speciﬁcfortheα67–76sequence(mainimmunogenicregion,
MIR) has been described previously [22]. The generation
of the recombinant human Fab fragments Fab35 and
Fab38 using a combinatorial cDNA thymus library from a
patientwiththymiclymphoidhyperplasiaandproductionof
autoantibodies speciﬁc for the anti-AChR γ-subunit has also
been described [21]. Fab35 and Fab38 were used to produce
scFvs by overlap extension PCR as shown in Figure 1.I n
detail for the production of VH-VL scFvs from Fab35 and
Fab38primerswereusedasindicatedinFigure 1.B yc ontrast
for VL-VH orientation of the scFvs the VL primers harboured
the SﬁI site at the 5
  end and the glycin/serin linker at the 3
 
end, whereas the VH primers had the glycin/serin linker at
the 5
  end and the NotI site at 3
  end. The primers are listed
in Table 2.
4.2. Production and Puriﬁcation of the Immunotoxins. The
protocol for the production and puriﬁcation of recombinant
immunotoxins was published previously [62]. Brieﬂy, E. coli
strain BL21DE3 pLysS (Stratagene, Heidelberg, Germany)
was transformed with the corresponding plasmids and single8 Journal of Biomedicine and Biotechnology
Table 2
Primers for scFv from Fab35/38 in orientation VH-VL
scFv/Fab35 VH5
  SﬁI: 5
 -AGTCTAACGTTCGGCCCAGCCGGCCTCGGGGGGCGACTTGGTCCAGCCGGGGGGG-3
 
scFv/Fab38 VH5
  Sﬁ I:5
 -AGTCTAACGTTCGGCCCAGCCGGCCTCGGGGGGAGGCGTGGTCCAGCCGGGGGGG-3
 
scFv/Fab35/38 VH3
  linker:5
 -GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCTGGAGAGACGGTGACCGTTGTCCCTTG
GCC-3
 
scFv/Fab35/38 VL5
  linker:5
 -GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCAGTGATGACCCAGTCTCCA-3
 
scFv/Fab35 VL3
  Not I:5
 -TGCTGCTGCGGCCGCTTTGATCTCCAGCTTGGTCCC-3
 
scFv/Fab38 VL3
  Not I: 5
 -TGCTGCTGCGGCCGCCGTGATCTCCAGCTTGGTCCC-3
 
Primers for scFv from Fab35/38 in orientation VL-VH
scFv/Fab35/38 VL5
  Sﬁ I: 5
 -ATGGCTCAGGGTTCGGCCCAGCCGGCCGTGATGACCCAGTCTCCA-3
 
scFv/Fab35 VL3
  linker: 5
 -GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCTTTGATCTCCAGCTTGGTCCC-3
 
scFv/Fab38 VL3
  linker:5
 -GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCCGTGATCTCCAGCTTGGTCCC-3
 
scFv/Fab35 VH5
  linker: 5
 -GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCATCGGGGGGCGACTTGGTCCAGCCGG
GGGGG-3
 
scFv/Fab38 VH5
  linker: 5
 -GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCATCGGGGGGAGGCGTGGTCCAGCCGG
GGGGG-3
 
scFv/Fab35/38 VH3
  Not I: 5
 -TGCTGCTGCGGCCGCTGGAGAGACGGTGACCGTTGTCCCTTGGCC-3
 
colonies used to inoculate 10mL LB medium containing
50μg/μL kanamycin. After 6–8 hours incubation at 26
◦C,
5mL was added to 50mL Terriﬁc Broth containing 0.5mM
ZnCl, 50μg/μL kanamycin, and shaken overnight at 26
◦C.
After 14–16 hours, the 50mL culture was used to inoculate
5 × 200mL Terriﬁc Broth supplemented as above and
incubated for further 3–5 hours at 26
◦C. The broth was
supplemented to ﬁnal concentrations of 0.5M sorbitol,
4% NaCl, and 40mM betain and allowed to stand for
30 minutes before protein synthesis was induced by IPTG
(ﬁnal concentration 2mM) and overnight shaking. After 20
hours, the bacteria were harvested by centrifugation (3700g,
4◦C), lysed in 75mM Tris.HCl (pH 9), 300mM NaCl, 10%
glycerol,5mMDTT,5mMEDTA,sonicatedandcentrifuged
at 25000g, 4◦C for 60 minutes. The supernatant was ﬁltered,
desalted on an FPLC column at a ﬂow rate of 6mL/minute
(Amersham Biosciences, Heidelberg, Germany), and pooled
protein fractions were puriﬁed and eluted by nickel-NTA-
agarose chromatography (Qiagen, Hilden, Germany) using
75mM Tris-HCl (pH 8.8), 10% glycerol, 1M NaCl, and
0.5M imidazol, at a ﬂow rate of 2mL/minute. Aliquots of
each fraction were separated by 10% SDS PAGE and proteins
were blotted onto nitrocellulose membranes as described
[63]. Fractions containing scFv35-ETA were pooled, con-
centrated by ultraﬁltration, and puriﬁed by size exclusion
chromatography using a Bio-Prep SE-100/17 column (Bio-
Rad) on the Aekta puriﬁer workstation (GE). Protein was
eluted with PBS (pH 7.4) and 1M NaCl, analyzed by SDS-
PAGE, quantiﬁed by densitometry (GS-700 Imaging Den-
sitometer, Bio-Rad) after Coomassie staining in comparison
with BSA standards, and veriﬁed by the Bradford assay
(Bio-Rad).
4.3. Cell Lines and Cell Culture Reagents. Cell lines were
obtained from American Type Culture Collection (Embry-
onal rhabdomyosarcoma: TE-671, RD, A-204, histiocytic
lymphoma: U937), German Collection of Microorganisms,
and Cell Cultures (Alveolar rhabdomyosarcoma: RH-30) or
were provided by Ewa Koscielniak (Olgahospital, Stuttgart,
Germany; embryonal rhabdomyosarcoma: FL-OH-1, alve-
olar rhabdomyosarcoma: Ax-OH-1). All cell lines were
cultured in RPMI 1640 (Gibco Invitrogen, Carlsbad, USA)
supplemented with 10% bovine calf serum (Biochrom
AG, Berlin, Germany), 100U/mL penicillin, and 100μg/mL
streptomycin (Gibco Invitrogen).
4.4. Flow Cytometry. The cell-binding activity of scFv35-
ETA was evaluated by ﬂow cytometry. Cell suspensions
containing 5 × 105 cells per mL were washed in PBS
incubated on ice with 1μg scFv35-ETA protein diluted
in 100μL PBS with 0.5% BSA. The cells were washed
again three times and treated with 100μL of the anti-ETA
monoclonal antibody TC-1 [63] (1 : 100) for 30 minutes.
After three further washes, the cells were incubated with
PE-labeled antimouse immunoglobulin (1 : 50; Jackson
ImmunoReseacrch Europe Ltd, Suﬀolk, GB) for 30 minutes
at 4◦C. Finally, cells were washed three further times and
analyzed on a FACScalibur (Becton Dickinson, Heidelberg,
Germany).
4.5. Colorimetric XTT Cytotoxicity Assay. The cytotoxicity
assay was performed as described [64]. Brieﬂy, 5 × 103 cell
per well was plated in 50μL on 96-well plates and let it
attach for 3 hours at 37
◦C. A serial dilution of scFv35-ETA
immunotoxin was applied in 50μL aliquot resulting in a
ﬁnal volume of 100μL. Plates were checked for chromogen
development 72 hours after immunotoxin application by
adding 50μL XTT/phenanzine methosulfate and further
incubation at 37
◦C for 4 hours. Absorbance was measured
at 450nm–630nm as reference wave length. Colorimetric
XTT conversion was also used in a competitive approach.
Therefore, scFv35-ETA was added with a ﬁnal constantJournal of Biomedicine and Biotechnology 9
concentration of 1.5nM to varying concentrations (1–
100molar excess) of scFv35.
4.6. Determination of IC50 Values. The concentration
required to achieve a 50% reduction of protein synthesis
(IC50) relative to untreated control cells was calculated using
GraphPad Prism 4. All measurements were performed in
triplicates.
4.7. Annexin V Apoptosis Assay. Induction of apoptosis was
measured by analysis of Ca2+-dependent binding of Annexin
V to phosphatidylserine on the cell surface of apoptotic cells
as described previously [33]. Brieﬂy, 5 × 105 RD cells were
seeded in 12-well plates in 1mL medium containing either
1μg scFv35-ETA or phosphate buﬀered saline as control in
triplicates. Cells were harvested after 12, 14, and 48 hours
of incubation at 37
◦C and incubated for 30 minutes on
ice with 500μL supernatant of Annexin V-eGFP-expressing
HEK293T cells supplemented with 10mM HEPES (pH 7.4),
150mM NaCl, 5mM KCl, and 2mM CaCl2. After washing
in PBS twice, ﬁnal measurements were performed under
the same buﬀer conditions with addition of 1 : 300 dilution
of Propidium Iodide (1mg/mL) on a FACScalibur (Becton
Dickinson, Heidelberg, Germany).
4.8. Generation and Treatment of RMS in an In Vivo SCID
Mouse Model. SCID mice were injected subcutaneously with
5 × 106 RD cells suspended in DMEM serum-free culture
medium on day 1 of the experiment. On days 2–10, the mice
received twice daily intraperioneal injections of either 10μg
scFv35-ETA (n = 6) or saline (n = 4), as described for other
toxins [62]. Tumor size was monitored transcutaneously on
days 4, 7, 10, 12, and 14 after inoculation of RD tumor cells
using a caliper. Tumor size was calculated according to the
formula: (length × width × height)/2.
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